Serotype survey of AAV gene delivery via subconjunctival injection in mice
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
AAV gene therapy approaches in the posterior eye resulted in the first FDA-approved gene therapy-based drug. However, application of AAV vectorology to the anterior eye has yet to enter even a Phase I trial. Furthermore, the simple and safe subconjunctival injection has been relatively unexplored in regard to AAV vector transduction. To determine the utility of this route for the treatment of various ocular disorders, a survey of gene delivery via natural AAV serotypes was performed and correlated to reported cellular attachment factors. AAV serotypes packaged with a self-complementary reporter were administered via subconjunctival injection to WT mice. Subconjunctival injection of AAV vectors was without incidence; however, vector shedding in tears was noted weeks following administration. AAV transduction was serotype dependent in anterior segment tissues including the eye lid, conjunctiva, and cornea, as well as the periocular tissues including muscle. Transgene product in the cornea was highest for AAV6 and AAV8, however, their corneal restriction was remarkably different; AAV6 appeared restricted to the endothelium layer while AAV8 efficiently transduced the stromal layer. Reported AAV cellular receptors were not well correlated to vector transduction; although, in some cases they were conserved among mouse and human ocular tissues. Subconjunctival administration of particular AAV serotypes may be a simple and safe targeted gene delivery route for ocular surface, muscular, corneal, and optic nerve diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Subconjunctival injection often utilize AAV8 and AAV6 for gene delivery67, and AAV8 is considered a reliable choice for suprachoroidal injections33,68,69.”
From An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species (2024) · cites this paper as [67]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 1×
“However, despite the recent FDA approval of the first commercial gene therapy for an ocular posterior disease, Leber’s Congenital Amaurosis (LCA) [1, 2], gene delivery based on adenoassociated virus (AAV) to various tissues in the anterior segment is relatively unexplored, especially following subconjunctival injectio…”
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864 · cited 2×
“cations, results from systemic AAV Phase I trials and our data raise environmental and safety concerns [29, 34].”
Gaudana, R., Ananthula, H. K., Parenky, A., & Mitra, A. K. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9183-3 · Cited by 1,406 · cited 1×
“1, subconjunctival injections distribute to a large periocular space, and are already in use for drug delivery to different target tissues, including the retina and optic nerve [45].”
Summerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406 · cited 4×
“S4, EGFR, 37/67 kDa Lam R, AAVR, and sialic acid were also present in the conjunctiva in mice, while the 37/67 kDa Lam R, AAVR, HSPG as well as sialic acid were also detected in mouse retina.”
InfluentialLong-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Adenovirus-Associated Defective Virus Particles
Atchison, R. W., Casto, B. C., & Hammon, W. M. (1965) · Science · doi:10.1126/science.149.3685.754 · Cited by 1,004 · cited 1×
“AAV is a small single-stranded DNA virus initially discovered in 1965 as a contaminant of an adenovirus preparation [5, 6].”
Nucleotide sequence and organization of the adeno-associated virus 2 genome
Srivastava, A., Lusby, E. W., & Berns, K. I. (1983) · Journal of Virology · doi:10.1128/jvi.45.2.555-564.1983 · Cited by 721
Production and characterization of adeno-associated viral vectors
Grieger, J. C., Choi, V. W., & Samulski, R. J. (2006) · Nature Protocols · doi:10.1038/nprot.2006.207 · Cited by 581 · cited 1×
“qPCR using SYBR green (Applied Biosystem) and Southern dot blotting with an P(32) labeled probe were employed to check the titers of the vector genome (vg) [54, 55]; viral purity was assessed by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) followed by silver staining using a kit (ThermoScientif…”
MethodAn essential receptor for adeno-associated virus infection
Pillay, S., Meyer, N. L., Puschnik, A. S., Davulcu, O., Diep, J., Ishikawa, Y., Jae, L. T., Wosen, J. E., Nagamine, C. M., Chapman, M. S., et al. (2016) · Nature · doi:10.1038/nature16465 · Cited by 532 · cited 5×
“S4, EGFR, 37/67 kDa Lam R, AAVR, and sialic acid were also present in the conjunctiva in mice, while the 37/67 kDa Lam R, AAVR, HSPG as well as sialic acid were also detected in mouse retina.”
InfluentialAkache, B., Grimm, D., Pandey, K., Yant, S. R., Xu, H., & Kay, M. A. (2006) · Journal of Virology · doi:10.1128/jvi.00878-06 · Cited by 430
Cited by
Gene Therapy in the Anterior Eye Segment
Amador, C., Shah, R., Ghiam, S., Kramerov, A. A., & Ljubimov, A. V. (2021) · Current Gene Therapy · doi:10.2174/1566523221666210423084233 · Cited by 93
Chowdhury, E. A., Meno‐Tetang, G. M. L., Chang, H. Y., Wu, S., Huang, H. W., Jamier, T., Chandran, J. S., & Shah, D. K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.017 · Cited by 82
AAV for Gene Therapy in Ocular Diseases: Progress and Prospects
He, X., Fu, Y., Ma, L., Yao, Y., Ge, S., Yang, Z. H., & Fan, X. (2023) · Research · doi:10.34133/research.0291 · Cited by 79
“Subconjunctival injection of AAV may be a simple and safe gene delivery strategy for the treatment of corneal, ocular surface, muscle, and optic nerve diseases [108].”
BackgroundAdeno-Associated Virus Mediated Gene Therapy for Corneal Diseases
Bastola, P., Song, L., Gilger, B. C., & Hirsch, M. L. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12080767 · Cited by 52
Self-citationOcular delivery of CRISPR/Cas genome editing components for treatment of eye diseases
Yu, W., & Wu, Z. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.011 · Cited by 50
Metadata
- Authors
- Song, L., Llanga, T., Conatser, L. M., Zaric, V., Gilger, B. C., & Hirsch, M. L.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- North Carolina State University (US)
- Corresponding author
- Hirsch, Matthew L.
- Venue
- Gene Therapy
- Published
- 2018-08-02
- Volume
- 25
- Issue
- 6
- Pages
- 402-414
- ISSN
- 0969-7128 (ISSN-L)
- 1476-5462
- PMC
- PMC11610513
- OpenAlex
- W2887065306
- Cited by
- 50
- References
- 58
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 5 · 2023: 6 · 2022: 5 · 2021: 5 · 2020: 12 · 2019: 6
- FWCI
- 3.53
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Gene Therapy (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Education Bureau of Hunan Province, 14B112
- U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (RO1AI072176-06A1)
- U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (RO1AR064369-01A1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Keywords
- adeno-associated virus serotypes, subconjunctival injection, AAV gene delivery, ocular gene therapy, AAV6, AAV8, anterior segment of the eye, mouse model
- MeSH terms
- Dependovirus, Animals, Conjunctiva, Cornea, Eye Diseases, Genetic Vectors, Humans, Surveys and Questionnaires, Transduction, Genetic, Genetic Therapy, Gene Transfer Techniques, Green Fluorescent Proteins, Mice, Serogroup
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serotype survey of AAV gene delivery via subconjunctival injection in mice. https://app.cochat.ai/papers/10.1038/s41434-018-0035-6
- The paper
- Song, L., Llanga, T., Conatser, L. M., Zaric, V., Gilger, B. C., & Hirsch, M. L. (2018). Serotype survey of AAV gene delivery via subconjunctival injection in mice. Gene Therapy. https://doi.org/10.1038/s41434-018-0035-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.